The World Health Organization defines pharmacovigilance, often known as drug safety, as "the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems." The ultimate purpose of pharmacovigilance is to ensure that medicines are used safely, with the dangers associated with the medical product being minimized and the benefits being maximized. It is critical in ensuring that doctors and patients have adequate information to make an informed decision when selecting a medicine for treatment. Mechanisms for evaluating and monitoring the safety of therapeutics in clinical use are critical for preventing or reducing harm to patients and consequently improving public health. In the next ten years, pharmacovigilance programs will briefly outline the probable ramifications of such tendencies on the evolution of science. In this global pitch, pharmacovigilance is confronting numerous problems in developing improved health care systems.
- Adverse Drug Reactions
- Drug Safety Monitoring
A C Matin
Stanford University, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Luis Jesus Villarreal Gomez
Autonomous University of Baja California, Mexico
John K Maesaka
NYU Langone Hospital Long Island, United States
Richard Denk
SKAN AG, Switzerland
Peter B Chase
Essentia Health- St. Mary's Medical Center, United States
Saliha Koc Aslan
Acibadem Healthcare Group, Turkey
Ana Isabel Rocha Faustino
University of Evora, Portugal
Narapereddy Krishna Prasad
Reckitt Benckiser LLC, United States
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Colon-specific scallop hydrolysates/Κ-carrageenan hydrogel loaded with curcumin alleviates dss-induced colitis through modulation of inflammatory cytokines and gut microbiota
Hai Tao Wu, Dalian Polytechnic University, China
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : General and local anaesthetic agents: An analysis of their safety data
Francesca Gargano, Campus Bio-Medico University of Rome, Italy
Title : 15,16-dihydrotanshinone-I-laden PLGA-co-PEG nanoparticles are potential therapeutic agents for the treatment of colorectal cancer by targeting the β-catenin/CD36 axis
Kwan Hiu Yee, Hong Kong Baptist University, China